Biomarkers Across Drug Development

Contributed by:

Denise Myshko

NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.

Biomarkers have a multitude of applications, such as detecting disease early on, identifying potential drug targets, predicting patient response to medication, and accelerating clinical trials. The promise of biomarkers to shorten drug development time and decrease costs in the long term is likely to act in tandem to spur growth in the biomarker analysis market, which has excellent potential, according to a recent report by Frost & Sullivan. “Biomarkers are central to an effective personalized healthcare strategy as they play an important role in determining not only the magnitude of the benefit patients will derive from a treatment, but also which patients will benefit,” says Hal Barron, global head, product development… Experts on this topic Hal Barron, Global Head, Product Development and Chief Medical Officer, at Roche Nagaraja Srivatsan, VP and Head of Life Sciences, North America, at Cognizant Kerri Schoedel, Ph.D., Scientific Director, Clinical Pharmacology, at Kendle Peter Smith, Ph.D., Senior VP, Nonclinical Development Sciences, at Millennium Pharmaceuticals Inc.: The Takeda Oncology Company Brian Sanderson, M.D., Medical Director, Chiltern Early Phase Alain Stricker-Krongrad, Ph.D., Chief Scientific Officer at Charles River Thomas Jones, Ph.D., Senior Director, Toxicology and Pathology, at Eli Lilly and Company Jerome Bailey, VP, Early Phase Business Center, at Omnicare Clinical Research Jamie Dananberg, M.D., Executive Director of Clinical Pharmacology at Eli Lilly and Company Murray Ducharme, Pharm.D., Chief Science Officer for Cetero Research

Posted in:

Post a Comment

You must be logged in to post a Comment.

FEEDBACK